New Alzheimer’s Drug, Donanemab, Shows Promise in Slowing Cognitive Decline

A new drug, donanemab, has demonstrated a meaningful slowing of cognitive decline in individuals with early symptomatic Alzheimer’s disease, according to results published in the New England Journal of Medicine on January 15, 2026.The phase 3 clinical trial, involving nearly 1,800 participants, offers a hopeful advancement in the fight against this devastating disease.

How Donanemab Works

Donanemab is an antibody designed to target and clear amyloid plaques, a hallmark of Alzheimer’s disease, from the brain. Unlike some previous approaches, donanemab specifically targets plaques composed of a modified form of amyloid beta, believed to be particularly toxic to brain cells. The trial focused on individuals with early symptomatic Alzheimer’s, meaning they had mild cognitive impairment or mild dementia and evidence of amyloid plaques in their brains.

Key Trial findings

The trial participants were randomly assigned to recieve either donanemab or a placebo intravenously every two weeks for up to 18 months. The primary outcome measure was the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, a measure of cognitive and functional decline.

Results showed that donanemab slowed cognitive decline by approximately 22% compared to placebo. This advancement was statistically significant and clinically meaningful, suggesting a tangible benefit for patients. Furthermore, a substantial proportion of participants (over 40%) who received donanemab showed no clinical progression of disease over the 18-month period.The study also indicated that the drug’s effect was more pronounced in individuals with lower levels of tau, another protein implicated in Alzheimer’s disease, suggesting that earlier intervention may be more effective.

Safety Considerations

Donanemab is not without risks. The most common side effects observed in the trial were infusion-related reactions, such as fever, chills, and nausea. More serious, though less frequent, side effects included amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or bleeding. ARIA was carefully monitored throughout the trial, and most cases were mild or asymptomatic. Though, the risk of ARIA necessitates careful patient selection and monitoring during treatment.The Food and Drug Administration (FDA) will carefully review the safety data as part of the drug approval process.

Implications for Alzheimer’s Treatment

The findings from the donanemab trial represent a significant step forward in Alzheimer’s research. While not a cure, the drug offers the potential to slow the progression of the disease and preserve cognitive function for a longer period.This could translate to a meaningful improvement in the quality of life for individuals with Alzheimer’s and their families.

However, several challenges remain.Early and accurate diagnosis of Alzheimer’s is crucial to identify individuals who may benefit from treatment. Widespread access to amyloid PET scans, which are used to detect amyloid plaques in the brain, is currently limited. Moreover, the long-term effects of donanemab are still unknown, and ongoing monitoring will be essential.

Eli Lilly, the manufacturer of donanemab, submitted the drug for FDA approval in 2024, with a decision expected in early 2026. If approved, donanemab will join a growing, though still limited, arsenal of treatments for Alzheimer’s disease.